Cargando…
Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review
In comparison to the general population, lung cancer patients are more likely to suffer from severe Coronavirus disease (COVID-19) and associated mortality. Considering this increased risk, and in order to prevent symptoms and severe disease, patients with lung cancer have been prioritized for COVID...
Autores principales: | Rodilla, Ananda M., Tavolacci, Sooyun, Cagan, Jazz, Shah, Tanay, Mittan, Sandeep, Mack, Philip C., Hirsch, Fred R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223259/ https://www.ncbi.nlm.nih.gov/pubmed/37243073 http://dx.doi.org/10.3390/vaccines11050969 |
Ejemplares similares
-
PP.48 Breakthrough SARS-CoV-2 Infection and COVID-19 Disease Severity in Lung Cancer Patients
por: Tavolacci, Sooyun, et al.
Publicado: (2023) -
OA06.03 Serological Response to SARS-CoV-2 Vaccination in Patients Lung Cancer: A Mount Sinai-Led Prospective Matched Controlled Study
por: Mack, P.C., et al.
Publicado: (2022) -
Assessment of Serology after Sars-Cov-2 Vaccine in Allogeneic HCT Recipients
por: Baker, Melissa, et al.
Publicado: (2021) -
Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer
por: Mack, Philip C., et al.
Publicado: (2022) -
Serological findings following the second and third SARS‐CoV‐2 vaccines in lung transplant recipients
por: Bárczi, Enikő, et al.
Publicado: (2022)